The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications

We report a computational approach that integrates structural bioinformatics, molecular modelling and systems biology to construct a drug-target network on a structural proteome-wide scale. The approach has been applied to the genome of Mycobacterium tuberculosis (M.tb), the causative agent of one of today's most widely spread infectious diseases. The resulting drug-target interaction network for all structurally characterized approved drugs bound to putative M.tb receptors, we refer to as the ‘TB-drugome’. The TB-drugome reveals that approximately one-third of the drugs examined have the potential to be repositioned to treat tuberculosis and that many currently unexploited M.tb receptors may be chemically druggable and could serve as novel anti-tubercular targets. Furthermore, a detailed analysis of the TB-drugome has shed new light on the controversial issues surrounding drug-target networks [1]–[3]. Indeed, our results support the idea that drug-target networks are inherently modular, and further that any observed randomness is mainly caused by biased target coverage. The TB-drugome (http://funsite.sdsc.edu/drugome/TB) has the potential to be a valuable resource in the development of safe and efficient anti-tubercular drugs. More generally the methodology may be applied to other pathogens of interest with results improving as more of their structural proteomes are determined through the continued efforts of structural biology/genomics.

[1]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[2]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[3]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[4]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[5]  Robert Stroud,et al.  Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. , 2006, Journal of medicinal chemistry.

[6]  A. Hopkins.  Network pharmacology , 2007, Nature Biotechnology.

[7]  Liang Shen,et al.  Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery , 2007, Genome Biology.

[8]  R. Russell,et al.  Modular architecture of nucleotide-binding pockets , 2010, Nucleic acids research.

[9]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[10]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[11]  Patric R. J. Östergård,et al.  A fast algorithm for the maximum clique problem , 2002, Discret. Appl. Math..

[12]  Sean R. Collins,et al.  Global landscape of protein complexes in the yeast Saccharomyces cerevisiae , 2006, Nature.

[13]  Ruben E. Valas,et al.  Nothing about protein structure classification makes sense except in the light of evolution. , 2009, Current opinion in structural biology.

[14]  J. Content,et al.  The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. , 2000, FEMS microbiology reviews.

[15]  R. Solé,et al.  The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.

[16]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[17]  S T Cole,et al.  Learning from the genome sequence of Mycobacterium tuberculosis H37Rv , 1999, FEBS letters.

[18]  Christopher M. Sassetti,et al.  Genetic requirements for mycobacterial survival during infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Lei Xie,et al.  Detecting evolutionary relationships across existing fold space, using sequence order-independent profile–profile alignments , 2008, Proceedings of the National Academy of Sciences.

[20]  J. Thornton,et al.  Conformational diversity of ligands bound to proteins. , 2006, Journal of molecular biology.

[21]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[22]  Philip E. Bourne,et al.  A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites , 2007, BMC Bioinformatics.

[23]  H. Kitano.  A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[24]  Pradeep K. Singh,et al.  Targeting a bacterial stress response to enhance antibiotic action , 2009, Proceedings of the National Academy of Sciences.

[25]  Emma Griffiths,et al.  Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr , 2008, Proceedings of the National Academy of Sciences.

[26]  YamanishiYoshihiro,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008 .

[27]  J. Betts,et al.  Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.

[28]  D. Fell,et al.  The small world inside large metabolic networks , 2000, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[29]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[30]  Patric R. J. Östergård,et al.  A New Algorithm for the Maximum-Weight Clique Problem , 1999, Electron. Notes Discret. Math..

[31]  M. Newman.  Clustering and preferential attachment in growing networks. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.

[32]  Aniko Simon,et al.  eHiTS: a new fast, exhaustive flexible ligand docking system. , 2007, Journal of molecular graphics & modelling.

[33]  C. Orengo,et al.  Plasticity of enzyme active sites. , 2002, Trends in biochemical sciences.

[34]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[35]  Marc A. Martí-Renom,et al.  MODBASE: a database of annotated comparative protein structure models and associated resources , 2005, Nucleic Acids Res..

[36]  Z. Neda,et al.  Measuring preferential attachment in evolving networks , 2001, cond-mat/0104131.

[37]  Liem Nguyen,et al.  Protein Kinase G Is Required for Intrinsic Antibiotic Resistance in Mycobacteria , 2009, Antimicrobial Agents and Chemotherapy.

[38]  Balasubramanian Gopal,et al.  Structural and Biophysical Studies on Two Promoter Recognition Domains of the Extra-cytoplasmic Function σ Factor σC from Mycobacterium tuberculosis* , 2007, Journal of Biological Chemistry.

[39]  Christian Cambillau,et al.  LppX is a lipoprotein required for the translocation of phthiocerol dimycocerosates to the surface of Mycobacterium tuberculosis , 2006, The EMBO journal.

[40]  Shekhar C Mande,et al.  Crystallization and preliminary X-ray crystallographic studies of Mycobacterium tuberculosis CRP/FNR family transcription regulator. , 2006, Acta crystallographica. Section F, Structural biology and crystallization communications.

[41]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[42]  K. Bostian,et al.  Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. , 2006, Biochemical pharmacology.

[43]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[44]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[45]  Philip E. Bourne,et al.  A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery , 2009, Bioinform..

[46]  J. Schultz,et al.  Adenylyl Cyclase Rv1264 from Mycobacterium tuberculosis Has an Autoinhibitory N-terminal Domain* , 2002, The Journal of Biological Chemistry.

[47]  Eugenio Uriarte,et al.  Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. , 2009, Molecular pharmaceutics.

[48]  J. Mestres,et al.  A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.

[49]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[50]  Jian Wang,et al.  In Silico Elucidation of the Molecular Mechanism Defining the Adverse Effect of Selective Estrogen Receptor Modulators , 2007, PLoS Comput. Biol..

[51]  Martin Phillips,et al.  Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Tanya Parish,et al.  Deletion of Two-Component Regulatory Systems Increases the Virulence of Mycobacterium tuberculosis , 2003, Infection and Immunity.

[53]  Min Zhang,et al.  Purification and characterization of a functionally active Mycobacterium tuberculosis pyrroline-5-carboxylate reductase. , 2006, Protein expression and purification.

[54]  Anang A. Shelat,et al.  Chemical genetics of Plasmodium falciparum , 2010, Nature.

[55]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[56]  John P. Overington,et al.  Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.

[57]  David Alland,et al.  Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase , 2003, Journal of Biological Chemistry.

[58]  P. Tonge,et al.  Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. , 2008, Accounts of chemical research.

[59]  L. A. Basso,et al.  Mycobacterial shikimate pathway enzymes as targets for drug design. , 2007, Current drug targets.

[60]  Alla Karnovsky,et al.  A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore , 2009, Proceedings of the National Academy of Sciences.

[61]  B. Gopal,et al.  Structural and biophysical studies on two promoter recognition domains of the extra-cytoplasmic function sigma factor sigma(C) from Mycobacterium tuberculosis. , 2007, The Journal of biological chemistry.

[62]  Michael Roth,et al.  Targeting QseC Signaling and Virulence for Antibiotic Development , 2008, Science.

[63]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..

[64]  R. Albert,et al.  The large-scale organization of metabolic networks , 2000, Nature.

[65]  Adam Godzik,et al.  Flexible structure alignment by chaining aligned fragment pairs allowing twists , 2003, ECCB.

[66]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[67]  Peter Sander,et al.  Characterization of a Mycobacterium tuberculosis mutant deficient in pH-sensing adenylate cyclase Rv1264. , 2006, International journal of medical microbiology : IJMM.

[68]  Shekhar C Mande,et al.  The TB structural genomics consortium: providing a structural foundation for drug discovery. , 2002, Current drug targets. Infectious disorders.

[69]  E. Rubin,et al.  Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[71]  Gunter Schneider,et al.  1.9 A structure of the signal receiver domain of the putative response regulator NarL from Mycobacterium tuberculosis. , 2008, Acta crystallographica. Section F, Structural biology and crystallization communications.

[72]  Jason Hinds,et al.  A member of the cAMP receptor protein family of transcription regulators in Mycobacterium tuberculosis is required for virulence in mice and controls transcription of the rpfA gene coding for a resuscitation promoting factor , 2005, Molecular microbiology.

[73]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[74]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[75]  Jordi Mestres,et al.  Computational chemogenomics approaches to systematic knowledge-based drug discovery. , 2004, Current opinion in drug discovery & development.

[76]  Philip E. Bourne,et al.  A Multidimensional Strategy to Detect Polypharmacological Targets in the Absence of Structural and Sequence Homology , 2010, PLoS Comput. Biol..

[77]  Bernhard O. Palsson,et al.  Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets , 2007 .

[78]  S. Klamt,et al.  GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism , 2007, Genome Biology.

[79]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[80]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[81]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[82]  E. Levanon,et al.  Preferential attachment in the protein network evolution. , 2003, Physical review letters.

[83]  Hiroki Kobayashi,et al.  Integrating Statistical Predictions and Experimental Verifications for Enhancing Protein-Chemical Interaction Predictions in Virtual Screening , 2009, PLoS Comput. Biol..

[84]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[85]  Roy Kishony,et al.  Drug interactions and the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.

[86]  Liem Nguyen,et al.  Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages , 2004, Science.

[87]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.

[88]  Daniel Kalman,et al.  Aligning antimicrobial drug discovery with complex and redundant host-pathogen interactions. , 2009, Cell host & microbe.

[89]  John T. Belisle,et al.  Mycobacterium tuberculosis LprG (Rv1411c): A Novel TLR-2 Ligand That Inhibits Human Macrophage Class II MHC Antigen Processing1 , 2004, The Journal of Immunology.

[90]  Andrew J. Crossthwaite,et al.  Higher-order organization and regulation of adenylyl cyclases. , 2006, Trends in pharmacological sciences.

[91]  A W Munro,et al.  The TB structural genomics consortium: a resource for Mycobacterium tuberculosis biology. , 2003, Tuberculosis.

[92]  S. Almo,et al.  Mycobacterium tuberculosis Universal Stress Protein Rv2623 Regulates Bacillary Growth by ATP-Binding: Requirement for Establishing Chronic Persistent Infection , 2009, PLoS pathogens.

[93]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[94]  Michal Brylinski,et al.  FINDSITELHM: A Threading-Based Approach to Ligand Homology Modeling , 2009, PLoS Comput. Biol..

[95]  Angelo D. Favia,et al.  Protein promiscuity and its implications for biotechnology , 2009, Nature Biotechnology.

[96]  R. Solé,et al.  Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.